ppp4cb Antibody

What is PPP4C and why is it important in research?

PPP4C (Protein Phosphatase 4 Catalytic Subunit) is a serine/threonine phosphatase with critical roles in numerous cellular processes. Also known as PP-X, Pp4, PP4C, PPP4, PPX, or Protein phosphatase X, PPP4C is ubiquitously transcribed in adult tissues, with relatively lower expression in muscle, brain, heart, and pancreas tissues . Its importance in research stems from:

• Its involvement in the Wnt signaling pathway, a fundamental pathway in development and disease

• Its potential role as a biomarker in multiple cancer types

• Its functions in pattern specification, morphogenesis, and tissue development, which are essential for embryogenesis

• Its implications in various pathological conditions, particularly in tumorigenesis

Current research shows PPP4C elevation has been documented in several cancer types including breast, lung, ovarian, colorectal, and pancreatic ductal tumors, making it a significant target for oncology research .

What types of PPP4C antibodies are commercially available for research?

Based on current commercial offerings, researchers typically have access to:

• Polyclonal antibodies: These recognize multiple epitopes on the PPP4C protein and are often derived from rabbit hosts. For example, the rabbit polyclonal Anti-PPP4C Antibody (A29956) detects endogenous levels of PPP4C protein .

• Monoclonal antibodies: While not specifically mentioned in the search results for PPP4C, monoclonal antibodies would provide more consistent results with minimal lot-to-lot variation when available.

When selecting an antibody, researchers should consider factors such as:

• The specific application requirements (WB, IHC, IF)

• Species reactivity (human, mouse, rat)

• The region of the protein targeted (epitope)

• The format (conjugated or unconjugated)

What applications can PPP4C antibodies be used for?

PPP4C antibodies have been validated for multiple applications in molecular and cellular biology research:

• Western Blotting (WB): For detecting PPP4C protein in cell or tissue lysates. Anti-PPP4C antibody A29956 is validated for WB applications .

• Immunohistochemistry (IHC): For visualizing PPP4C in tissue sections. This can be particularly valuable for cancer research where PPP4C expression may be altered .

• Immunofluorescence (IF): For subcellular localization studies of PPP4C in fixed cells .

• Co-immunoprecipitation (Co-IP): Though not directly mentioned for the A29956 antibody, Co-IP can be used to study protein-protein interactions, as demonstrated in research showing Ppp4c interacts with AXIN1 .

The choice of application should be guided by experimental questions and the validated performance of the specific antibody for each technique.

How do I choose between monoclonal and polyclonal antibodies for PPP4C detection?

The decision between monoclonal and polyclonal antibodies should be based on your specific research needs:

Monoclonal antibodies:

• Provide high specificity and consistency

• Exhibit minimal lot-to-lot variation

• Best for applications requiring precise epitope recognition

• Ideal for long-term studies where consistency is crucial

Polyclonal antibodies:

• Recognize multiple epitopes on the target protein

• Often provide stronger signals due to multiple binding sites

• More likely to successfully detect PPP4C across various assay conditions

• Better at detecting both native and denatured forms of the protein

For PPP4C detection specifically, polyclonal antibodies like A29956 can be advantageous when working across multiple applications (WB, IHC, IF) as they bind to several different epitopes, increasing the likelihood of successful detection under various experimental conditions .

What is the role of PPP4C in Wnt signaling, and how can PPP4C antibodies be used to study this pathway?

PPP4C has been identified as a component of the Wnt signaling pathway, which is crucial for development and implicated in cancer. Key findings regarding this relationship include:

• PPP4C can enhance canonical Wnt signaling at the destruction complex level

• PPP4C interacts with AXIN1 in vivo, as demonstrated by co-immunoprecipitation assays

• PPP4C inhibits AXIN1 abundance, thereby promoting canonical Wnt signaling

• Loss of Ppp4c (via knockdown) has been shown to compromise Wnt responses in embryo models

Researchers can use PPP4C antibodies to study this pathway through:

• Co-immunoprecipitation experiments: To investigate protein-protein interactions between PPP4C and Wnt pathway components (e.g., AXIN1, β-catenin)

• Western blotting: To quantify changes in PPP4C levels in response to Wnt pathway activation or inhibition

• Immunofluorescence: To examine co-localization of PPP4C with Wnt pathway components

Experimental design should include appropriate controls, such as Wnt pathway activators (e.g., Wnt3a) or inhibitors, and careful validation of antibody specificity for PPP4C detection.

How can PPP4C antibodies be utilized for cancer research and biomarker studies?

PPP4C has significant potential as a cancer biomarker, with multiple studies showing its diagnostic and prognostic value:

The table below summarizes the diagnostic accuracy of PPP4C across several cancer types:

Selected cancer types with highest AUC values shown

PPP4C antibodies can be utilized in cancer research through:

• Immunohistochemistry on tissue microarrays: To evaluate PPP4C expression across different tumor stages and grades

• Western blotting of patient samples: To quantify PPP4C levels and correlate with clinical outcomes

• Combining with other biomarkers: To develop multi-marker panels with improved diagnostic or prognostic value

When designing such studies, researchers should consider using standardized protocols for antibody-based detection and including appropriate normal tissue controls.

How can I validate the specificity of a PPP4C antibody for my research?

Validating antibody specificity is crucial for reliable research results. For PPP4C antibodies, consider these validation approaches:

• Positive and negative controls:

  • Use tissue or cell lines with known high (e.g., many cancer cell lines) and low (e.g., muscle tissue) PPP4C expression

  • Include PPP4C knockout or knockdown samples as negative controls

• Multiple detection methods:

  • Compare results across different techniques (Western blot, IHC, IF)

  • Verify protein size (approximately 35 kDa for PPP4C)

• Epitope verification:

  • Use competing peptides corresponding to the immunogen

  • Compare results from antibodies targeting different epitopes of PPP4C

• Correlation with mRNA levels:

  • Verify that protein detection correlates with PPP4C transcript levels in the same samples

• Reproducibility testing:

  • Test the antibody under various conditions (different fixatives, incubation times, etc.)

  • Ensure consistent results across independent experiments

Drawing from methods used for other antibody validations, additional approaches can include using orthogonal methods that don't rely on antibody binding, such as mass spectrometry, to confirm identification of the protein being detected .

What is the optimal protocol for Western blotting with PPP4C antibodies?

Based on validated protocols for antibodies like Anti-PPP4C Antibody (A29956), here is an optimized Western blotting protocol:

Sample Preparation:

• Lyse cells or tissues in RIPA buffer supplemented with protease inhibitors

• Quantify protein concentration using BCA or Bradford assay

• Prepare samples containing 20-40 μg of total protein in Laemmli buffer with reducing agent

• Denature samples at 95°C for 5 minutes

Gel Electrophoresis and Transfer:

• Resolve proteins on a 10-12% SDS-PAGE gel (PPP4C is approximately 35 kDa)

• Transfer to PVDF or nitrocellulose membrane at 100V for 1 hour or 30V overnight

Antibody Incubation:

• Block membrane with 5% non-fat milk in TBST for 1 hour at room temperature

• Incubate with primary PPP4C antibody at 1:1000 dilution in blocking buffer overnight at 4°C

• Wash 3x with TBST, 5 minutes each

• Incubate with appropriate HRP-conjugated secondary antibody (e.g., Goat Anti-Rabbit IgG H&L Antibody) at 1:5000 dilution for 1 hour at room temperature

• Wash 3x with TBST, 5 minutes each

Detection:

• Apply ECL substrate and expose to X-ray film or image using a digital imaging system

• Expect to detect a band at approximately 35 kDa for PPP4C

Controls to Include:

• Positive control: Lysate from cells known to express PPP4C

• Loading control: Probe for housekeeping proteins like GAPDH or β-actin

• Negative control: If available, lysate from PPP4C-knockdown cells

How should I optimize immunohistochemistry protocols for PPP4C detection in tissue samples?

For effective immunohistochemical detection of PPP4C in tissue sections:

Tissue Preparation:

• Fix tissues in 10% neutral buffered formalin for 24-48 hours

• Process and embed in paraffin

• Section at 4-5 μm thickness onto positively charged slides

Antigen Retrieval:

• Deparaffinize and rehydrate sections through xylene and graded alcohols

• Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Maintain at 95-98°C for 15-20 minutes, then cool gradually

Staining Procedure:

• Block endogenous peroxidase activity with 3% hydrogen peroxide for 10 minutes

• Block non-specific binding with 5% normal goat serum for 1 hour

• Incubate with primary PPP4C antibody at optimized dilution (start with 1:100) overnight at 4°C

• Wash 3x with PBS

• Apply appropriate detection system (e.g., polymer-based HRP detection)

• Develop with DAB chromogen and counterstain with hematoxylin

• Dehydrate, clear, and mount

Optimization Recommendations:

• Perform antibody titration (1:50 to 1:500) to determine optimal concentration

• Compare different antigen retrieval methods (heat vs. enzymatic, different pH buffers)

• Test various incubation times and temperatures for primary antibody

• Include appropriate positive control tissues (e.g., tissues known to express PPP4C)

• Include negative controls (omission of primary antibody, isotype control)

When analyzing cancer tissues, consider the differential expression patterns of PPP4C across various tumor types as reported in the literature .

What are common troubleshooting issues with PPP4C antibodies and how can they be resolved?

Researchers may encounter several challenges when working with PPP4C antibodies. Here are common issues and solutions:

Issue 1: No signal in Western blot

• Possible causes: Insufficient protein, degraded antibody, ineffective transfer

• Solutions:

  • Increase protein loading (50-80 μg)

  • Verify antibody activity with a positive control

  • Optimize transfer conditions for proteins around 35 kDa

  • Extend primary antibody incubation time or increase concentration

  • Try different blocking agents (BSA vs. milk)

Issue 2: Non-specific bands

• Possible causes: Antibody cross-reactivity, excessive antibody concentration, insufficient blocking

• Solutions:

  • Increase blocking time or concentration

  • Optimize antibody dilution (try more dilute solutions)

  • Include additional washing steps

  • Use freshly prepared buffers

  • Consider using monoclonal antibodies for higher specificity

Issue 3: Inconsistent results in IHC

• Possible causes: Variability in fixation, antigen masking, tissue processing differences

• Solutions:

  • Standardize fixation protocols (time, fixative type)

  • Optimize antigen retrieval conditions for each tissue type

  • Use automated staining platforms if available

  • Include known positive control tissues in each batch

Issue 4: High background in immunofluorescence

• Possible causes: Autofluorescence, non-specific binding, excessive antibody

• Solutions:

  • Pre-treat samples to reduce autofluorescence

  • Use appropriate blocking serum matched to secondary antibody host

  • Include 0.1-0.3% Triton X-100 in antibody diluent for better penetration

  • Extend washing steps after secondary antibody incubation

Drawing from approaches used with other antibodies, determining the antibody's epitope can help in understanding potential cross-reactivity issues and optimizing detection protocols .

How can I use PPP4C antibodies to study protein-protein interactions in the Wnt signaling pathway?

To investigate PPP4C's interactions with Wnt pathway components, researchers can employ these methodological approaches:

Co-immunoprecipitation (Co-IP):

• Prepare cell/tissue lysates in non-denaturing buffer containing protease inhibitors

• Pre-clear lysate with protein A/G beads

• Incubate lysate with PPP4C antibody (or tag-specific antibody for tagged PPP4C) overnight at 4°C

• Add protein A/G beads and incubate for 2-4 hours

• Wash beads thoroughly (4-5 times)

• Elute bound proteins and analyze by Western blot for Wnt pathway components (e.g., AXIN1, β-catenin)

As demonstrated in published research, this approach successfully showed that Ppp4c-HA immunoprecipitates retrieved Myc-AXIN1 in embryo animal cap tissue .

Proximity Ligation Assay (PLA):

• Fix cells on coverslips using 4% paraformaldehyde

• Permeabilize with 0.1% Triton X-100

• Block with appropriate serum

• Incubate with primary antibodies: anti-PPP4C and antibody against target protein (e.g., AXIN1)

• Follow PLA protocol with appropriate PLA probes

• Analyze under fluorescence microscope for PLA signals indicating protein proximity

Reciprocal Co-IP Controls:
Always include reciprocal experiments where the interaction partner (e.g., AXIN1) is immunoprecipitated and PPP4C is detected in the immunoprecipitate. This approach confirmed the PPP4C-AXIN1 interaction in previous studies .

Domain Mapping:
To identify specific interaction domains, use truncated mutants of interaction partners. In published research, co-IP of Ppp4c-HA with truncated Myc-AXIN1 mutants showed that Ppp4c interacts with AXIN1 through its C-terminal halves .

How can PPP4C antibodies be used to investigate its role as a cancer biomarker?

Based on the significant diagnostic and prognostic potential of PPP4C in multiple cancer types, researchers can employ PPP4C antibodies to:

• Develop tissue microarray (TMA) analyses:

  • Screen large cohorts of different cancer types using standardized IHC protocols

  • Correlate PPP4C expression with clinical parameters including stage, grade, and patient outcomes

  • The high diagnostic accuracy (AUC values >0.9) in cancers like BLCA, BRCA, CHOL, and GBM makes these prime candidates for focused studies

• Investigate mechanistic roles in tumorigenesis:

  • Compare PPP4C levels between paired tumor and adjacent non-tumor tissues

  • In cancers where PPP4C is a risk factor (ACC, BRCA, HNSC, etc.), examine downstream effects of PPP4C overexpression

  • In cancers where PPP4C is protective (CESC, READ, THYM), investigate potential tumor-suppressive mechanisms

• Develop multiplexed detection systems:

  • Combine PPP4C antibodies with antibodies against other cancer biomarkers

  • Use techniques like multiplexed immunofluorescence to create multi-parameter biomarker panels

PPP4C's consistent overexpression in multiple tumor types compared to normal tissues (significantly increased in 27/31 tumor types) provides strong rationale for further biomarker development studies .

What are the latest approaches for designing highly specific antibodies against phosphatases like PPP4C?

Recent advances in antibody engineering and selection technologies offer promising approaches for developing next-generation PPP4C antibodies:

• Computational antibody design:

  • Using inference methods from high-throughput sequencing data to predict antibody binding properties

  • Identifying different binding modes associated with specific ligands to design antibodies with customized specificity profiles

  • This approach has been validated experimentally in creating antibodies with either specific high affinity for particular targets or cross-specificity for multiple targets

• Phage display optimization:

  • Recent studies have employed phage-display experiments with minimal antibody libraries where CDR3 regions are systematically varied

  • High-throughput sequencing of selected antibodies allows for comprehensive mapping of binding specificity

  • These approaches could be adapted to generate PPP4C antibodies with precisely defined epitope recognition

• Epitope-focused strategies:

  • Targeting unique regions of PPP4C to avoid cross-reactivity with other phosphatases

  • For highly specific detection, focusing on regions that differentiate PPP4C from related phosphatases like PP2A

  • This approach was successful in generating specific monoclonal antibodies against other challenging targets like PAR4

These advanced approaches could overcome current limitations in phosphatase antibody specificity, which is particularly important given the structural similarities among phosphatase family members.

What are the key publications for researchers working with PPP4C antibodies?

While the search results don't provide an exhaustive list of PPP4C antibody publications, researchers should be aware of these key studies:

Researchers new to PPP4C should consider reviewing these publications as a foundation for understanding both the biological functions of PPP4C and the technical aspects of working with PPP4C antibodies.

What are the most reliable commercial sources for PPP4C antibodies?

Based on the search results, researchers seeking PPP4C antibodies should consider:

• Anti-PPP4C Antibody (A29956) - A rabbit polyclonal antibody validated for WB, IHC, and IF applications with reactivity to human, mouse, and rat samples. This antibody:

  • Detects endogenous levels of PPP4C protein

  • Recognizes a protein of approximately 35 kDa

  • Has been affinity-purified with purity >95% by SDS-PAGE

  • Is available in different sizes (50μl or 100μl)

When selecting any commercial antibody, researchers should:

• Review validation data provided by the manufacturer

• Check for peer-reviewed publications using the specific antibody

• Consider the antibody format and applications validated

• Verify reactivity with species of interest